ArticleJACC. Case reports2025
Treating Concomitant Advanced Heart Failure and Advanced Cancer With Left Ventricular Assist Device, Surgery, and Biologics.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The diagnosis of cancer in the context of evaluation for advanced heart failure therapies represents a psychosocial and therapeutic challenge. We present a case report of a patient with breast cancer diagnosed during heart transplantation evaluation. A 63-year-old female presented with anterior ST-segment elevation myocardial infarction and severe left ventricular dysfunction 2 months prior. She was readmitted because of heart failure decompensation and diagnosed with inotrope-dependent stage D heart failure. Routine pre-heart transplantation evaluation diagnosed Stage IIIb breast cancer. She underwent left ventricular assist device (LVAD) implantation, neoadjuvant chemo-immunotherapy, mastectomy, adjuvant radiation, and adjuvant immunotherapy. Three years after LVAD implantation, she is at home with cancer in remission. There are no direct guidelines for the management of active cancer in the setting of advanced heart failure. Multidisciplinary teams should rapidly evaluate patients with cancer and advanced heart failure to plan life-saving cardiac and oncologic therapies. The treatment of cancer in LVAD patients is an important area for future expansion of guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.